Xspray Pharma AB (publ) (STO:XSPRAY)

Market Cap	1.17B -8.9%
Revenue (ttm)	2.47M
Net Income	-164.51M
EPS	-4.16
Shares Out	47.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,506
Average Volume	115,301
Open	25.35
Previous Close	25.35
Day's Range	24.45 - 25.60
52-Week Range	23.10 - 64.10
Beta	-0.06
RSI	44.69
Earnings Date	May 6, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XSPRAY